Open Up a World
With DUPIXENT, you can help
prevent severe
exacerbations^1-3

Patients on Medium-to-High ICS
Dose + One or More Controller

Powerful reduction in severe exacerbations through Week 24^1,a

up to

81^%

reduction
in severe exacerbations
through Week 24
Rate ratio: 0.19 (95% CI: 0.07, 0.56)^1,a

Up to 81% reduction in severe exacerbations^a through Week 24 with DUPIXENT 300 mg Q2W + SOC (n=64) vs
placebo + SOC (n=68) (0.20 vs 1.04; rate ratio: 0.19 [95% CI: 0.07, 0.56]) (baseline blood EOS ≥300 cells/µL,
DRI12544, secondary endpoint).¹

QUEST primary endpoint results (ITT population)^1,2

48% reduction in severe exacerbations at Week 52 with DUPIXENT 200 mg Q2W + SOC (n=631) vs placebo + SOC (n=317) (rate ratio: 0.52 [95% CI: 0.41, 0.66])
46% reduction in severe exacerbations at Week 52 with DUPIXENT 300 mg Q2W + SOC (n=633) vs placebo + SOC (n=321) (rate ratio: 0.54 [95% CI: 0.43, 0.68])

^aDRI12544/QUEST: Severe exacerbations were defined as deterioration of asthma requiring the use of SCS for at least 3 days or hospitalization or ED visit due to asthma that required SCS.¹

DUPIXENT eliminated severe exacerbations in a majority of patients for up to 3 years^4,b

97^%

of patients
did not have an exacerbation requiring hospitalization or ED visit
in 3 years^3,b

Patients rolled over from DRI12544 and QUEST treated with DUPIXENT 300 mg Q2W + SOC (n=2062) during
the second and third years in the OLE period (TRAVERSE OLE, secondary endpoint)^c,d

ZERO

exacerbations
in 89% of patients in Year 3^4,b

Zero EXACERBATIONS^b IN 89% OF PATIENTS FROM QUEST IN YEAR 3⁴

(Weeks 48-96) when treated with DUPIXENT 200 mg/300 mg Q2W + SOC (n=816) for 52 weeks in
QUEST and continued with DUPIXENT 300 mg Q2W + SOC in the OLE period (TRAVERSE OLE, other
endpoint).

79.5% of patients rolled over from DRI12544 (n=396) experienced 0 exacerbations during
Weeks 48-96⁴
74% of patients rolled over from DRI12544 and QUEST (n=2062) experienced
0 exacerbations over ~3 years of treatment with DUPIXENT³

Results are descriptive. Definitive conclusions cannot be made.

Data were not multiplicity controlled and there are limitations associated with open-label study design, including lack of comparator arm, decreasing sample size, and potential continued involvement of responders and attrition of nonresponders.

^bTRAVERSE OLE: Severe asthma exacerbations were defined as requiring SCS for ≥3 days, hospitalization, or ED visit.⁴

^cAnalysis includes DRI12544 and QUEST patients enrolled in TRAVERSE.³

^dOf the 542 patients who experienced at least 1 severe asthma exacerbation, 66 (3.2% of the overall study population) had an exacerbation that required hospitalization or ED visit during the TRAVERSE study period (unadjusted annualized event rate of 0.027).³

DUPIXENT reduced severe exacerbations across EOS levels at Week 52³

PATIENTS WITH ELEVATED EOS (QUEST, PRESPECIFIED SUBGROUP ANALYSIS)^1,3

Annualized rate of severe exacerbations

EOS ≥150 CELLS/μL^e

1.08

Placebo + SOC
(n=237)

60%
REDUCTION
Rate ratio:
0.40
(95% CI:
0.31, 0.53)

0.43

DUPIXENT
300 mg Q2W +
SOC (n=452)

EOS ≥300 CELLS/μL

1.24

Placebo + SOC
(n=142)

67%
REDUCTION
Rate ratio:
0.33
(95% CI:
0.23, 0.45)

0.40

DUPIXENT
300 mg Q2W +
SOC (n=277)

EOS ≥500 CELLS/μL

1.25

Placebo + SOC
(n=74)

71%
REDUCTION
Rate ratio:
0.29
(95% CI:
0.18, 0.45)

0.36

DUPIXENT
300 mg Q2W + SOC
(n=141)

WEEK 52

Reductions in severe exacerbations when added to SOC. No statistically significant differences were observed during the 52-week treatment period in patients with baseline blood EOS <150 cells/μL taking DUPIXENT 200 mg Q2W or 300 mg Q2W + SOC and in the ≥150 to <300 cells/μL EOS subgroup treated with DUPIXENT 200 mg Q2W + SOC vs matching placebo + SOC.^1,3

DUPIXENT trials enrolled patients with EOS levels up to 1500 cells/μL.¹

^eSecondary endpoint.³

PATIENTS WITH ELEVATED EOS + ALLERGIC ASTHMA (QUEST, POST HOC ANALYSIS)^1,3

Annualized rate of severe exacerbations

EOS ≥150 CELLS/μL
+ ALLERGIC

1.05

Placebo + SOC
(n=136)

55%
REDUCTION
Rate ratio:
0.45
(95% CI:
0.31, 0.65)

0.47

DUPIXENT
300 mg Q2W + SOC
(n=260)

EOS ≥300 CELLS/μL
+ ALLERGIC

1.15

Placebo + SOC
(n=80)

62%
REDUCTION
Rate ratio:
0.38
(95% CI:
0.24, 0.60)

0.44

DUPIXENT
300 mg Q2W + SOC
(n=153)

EOS ≥500 CELLS/μL
+ ALLERGIC

1.20

Placebo + SOC
(n=41)

68%
REDUCTION
Rate ratio:
0.32
(95% CI:
0.18, 0.59)

0.39

DUPIXENT
300 mg Q2W + SOC
(n=70)

WEEK 52

Results are descriptive. Definitive conclusions cannot be made as this was a post-hoc analysis. There are limitations on sample size and data
were not multiplicity controlled.

Allergic asthma was defined as total serum IgE ≥30 IU/mL + ≥1 positive perennial-aeroallergen–specific IgE ≥0.35 kU/L at baseline.⁵

ED, emergency department; EOS, eosinophils; ICS, inhaled corticosteroid; OLE, open-label extension; Q2W, once every 2 weeks; SCS, systemic corticosteroid; SOC, standard of care.

Patients on Medium
ICS Dose + One
or
More Controller

DUPIXENT reduced
severe exacerbations
through Week 52^3,f

up to

71^%

reduction
in severe exacerbations
through Week 52^3,f

^fDRI12544/QUEST: Severe exacerbations were defined as deterioration of asthma requiring the use of SCS for at least 3 days or hospitalization or ED visit due to asthma that required SCS.¹

BASELINE BLOOD EOS ≥300 CELLS/µL & MEDIUM ICS DOSE > QUEST
(POST HOC ANALYSIS)³

71% reduction in severe exacerbations^f through Week 52 with DUPIXENT 300 mg Q2W + SOC (n=129) vs placebo + SOC (n=61) (rate ratio: 0.29 [95% CI: 0.17, 0.51]) (baseline blood EOS ≥300 cells/μL, QUEST, post hoc analysis).³

73% reduction in severe exacerbations through Week 52 with DUPIXENT 200 mg Q2W + SOC (n=134) vs placebo + SOC (n=68) (rate ratio: 0.27 [95% CI: 0.15, 0.48]) (baseline blood EOS ≥300 cells/μL, QUEST, post hoc analysis)³

Results are descriptive. Definitive conclusions cannot be made as this was a post hoc analysis. There are limitations on sample size and data were not multiplicity controlled.

DUPIXENT eliminated
severe exacerbations in
a majority of patients for
up to 3 years^3,4,g

ZERO

exacerbations
in 70% of patients in Year 3^3,4,g

^gTRAVERSE OLE: Severe asthma exacerbations were defined as requiring SCS for ≥3 days, hospitalization,
or ED visit.²

BASELINE BLOOD EOS ≥300 CELLS/µL & MEDIUM ICS DOSE > TRAVERSE OLE STUDY (POST HOC ANALYSIS)^3,4

Zero exacerbations^g in 70% of patients from QUEST in Year 3²

(Week 96) when treated with DUPIXENT 300 mg Q2W + SOC (n=215) for 52 weeks in QUEST and continued with DUPIXENT 300 mg Q2W + SOC in the OLE period (baseline blood EOS ≥300 cells/μL, TRAVERSE OLE study, post hoc analysis).^3,4

Results are descriptive. Definitive conclusions cannot be made as this was a post hoc analysis of open-label extension data.

Consider DUPIXENT sooner
for your appropriate
asthma patients on
medium ICS dose + one
or more controller^1,2

ED, emergency department; EOS, eosinophils;
ICS, inhaled corticosteroid; OLE, open-label
extension; Q2W, once every 2 weeks; SCS,
systemic corticosteroid; SOC, standard of care.

Consider DUPIXENT sooner for your appropriate asthma patients on medium ICS dose + one or more controller^1,2

ED, emergency department; EOS, eosinophils; ICS, inhaled corticosteroid; OLE, open-label extension; Q2W, once every 2 weeks; SCS, systemic corticosteroid; SOC, standard of care.

QUEST

FeNO ≥25 ppb^b,c

61% REDUCTION IN SEVERE EXACERBATIONS
AT WEEK 52

with DUPIXENT 300 mg + SOC (n=310)
vs placebo + SOC (n=172) (rate ratio: 0.39 [95% CI: 0.28, 0.54]) (prespecified subgroup analysis)¹

65% reduction in severe exacerbations
at Week 52 with DUPIXENT 200 mg +
SOC (n=299) vs placebo + SOC (n=162)
(rate ratio: 0.35 [95% CI: 0.25, 0.50]) (prespecified subgroup analysis)¹

EOS ≥500 cells/μL

71% REDUCTION IN SEVERE EXACERBATIONS
AT
WEEK 52

with DUPIXENT 300 mg + SOC
(n=141) vs placebo + SOC (n=74) (rate
ratio: 0.29 [95% CI: 0.18, 0.45])
(secondary endpoint)¹

74% reduction in severe exacerbations
at Week 52 with DUPIXENT 200 mg +
SOC (n=145) vs placebo +
SOC (n=76) (rate ratio: 0.26 [95% CI:
0.16, 0.40])¹

IgE ≥30 IU/mL and
EOS ≥300 cells/μL^b

62% REDUCTION IN SEVERE EXACERBATIONS
AT
WEEK 52

with DUPIXENT 300 mg + SOC (n=153)
vs placebo + SOC (n=80) (0.44 [95% CI: 0.32, 0.60] vs 1.15 [95% CI: 0.84, 1.59]; rate ratio: 0.38) (post hoc analysis)²

57% reduction in severe exacerbations
at Week 52 with DUPIXENT 200 mg +
SOC (n=148) vs placebo + SOC (n=89)
(0.39 [95% CI: 0.28, 0.54] vs 0.90 [95% CI:
0.64, 1.25]; rate ratio: 0.43) (post hoc analysis)²

Explore the SAFETY
DATA AND STUDY DESIGNS

VIEW safety data SEE THE FULL STUDY DESIGNS

Dosage and Administration

See the multiple dosage and administration
options for patients on DUPIXENT.

Explore ADMINISTRATION Options

Exacerbation Reduction in Patients 12+ Years

Open Up a World With DUPIXENT, you can help prevent severe exacerbations1-3

Open Up a World With DUPIXENT, you can help prevent severe exacerbations1-3

Powerful reduction in severe exacerbations through Week 241,a

reduction in severe exacerbations through Week 24 Rate ratio: 0.19 (95% CI: 0.07, 0.56)1,a

DUPIXENT eliminated severe exacerbations in a majority of patients for up to 3 years4,b

of patients did not have an exacerbation requiring hospitalization or ED visit in 3 years3,b

exacerbations in 89% of patients in Year 34,b

DUPIXENT reduced severe exacerbations across EOS levels at Week 523

PATIENTS WITH ELEVATED EOS (QUEST, PRESPECIFIED SUBGROUP ANALYSIS)1,3

PATIENTS WITH ELEVATED EOS + ALLERGIC ASTHMA (QUEST, POST HOC ANALYSIS)1,3

DUPIXENT reduced severe exacerbations through Week 523,f

reduction in severe exacerbations through Week 523,f

DUPIXENT eliminated severe exacerbations in a majority of patients for up to 3 years3,4,g

exacerbations in 70% of patients in Year 33,4,g

Consider DUPIXENT sooner for your appropriate asthma patients on medium ICS dose + one or more controller1,2